Background: Zoledronic acid, a third-generation amino bisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.
Aim: To determine whether the Zoledronic acid 12 weeks regimen was equal to the Zoledronic acid 4 weeks regimen for safety profile with bone metastasis or not.
Patients and Methods: The study is a randomized, clinical trial that was conducted at the Clinical Oncology Department, Zagazig university hospitals in the period from December 2017 to December 2019. Patients with bone metastasis were enrolled in the study. Patients were randomized to receive zoledronic acid every 12 weeks (n = 54) group A vs. every 4 weeks (n = 54) group B for 2 years. Both groups were compared regarding the safety of Zoledronic acid.
Results: The studied groups A and B were matched regarding age and sex distribution. All patients in both groups had pre-treatment normal serum creatinine and serum calcium levels. There was no significant difference between group A and group B regarding post-treatment serum calcium and serum creatinine (p-value=0.243and 0.489) respectively. All patients in both groups did not have osteonecrosis of the jaw.
Conclusion: Zoledronic acid every 12 weeks regimen was equal to zoledronic acid every 4 weeks regimen for safety profile in patients with bone metastasis.